变应性鼻炎患者舌下免疫治疗中外周血BATF及相关因子的表达
摘要
目的探讨IL-17、IL-21及BATF、RORγt基因在变应性鼻炎发病机制中的作用及舌下免疫治疗对其表达的影响。方法收集舌下免疫治疗的变应性鼻炎患者治疗前、治疗3月后、治疗6月后及健康对照组外周血,分离单个核细胞,收集血清。ELISA检查血IL-17、IL-21浓度;实时荧光定量PCR检测外周血单个核细胞中BATF、RORγt mRNA表达。结果变应性鼻炎患者治疗前血清IL-17、IL-21水平与正常对照组及治疗后有差异,差异有统计学意义(P<0.05);在舌下免疫治疗过程中IL-17、IL-21水平随治疗时间的延长而降低,差异有统计学意义(P<0.05)。变应性鼻炎患者治疗前BATF、RORγt mRNA表达较对照组及治疗后高,差异有统计学意义(P<0.05);在舌下免疫治疗过程中BATF、RORγt mRNA随治疗时间的延长而降低,差异有统计学意义(P<0.05)。结论 IL-17、IL-21与变应性鼻炎的发生、发展相关;BATF可能通过上调IL-17、IL-21的表达来促进变应性鼻炎的发生;舌下免疫治疗可能通过作用于BATF,RORγt环节减少IL-17、IL-21等炎症介质的分泌,从而改善过敏症状。
引文
[1]De Bot Cindy Ma R?der Esther.et al.Sensitisation patterns and association with age,gender,and clinical symptoms in children with allergic rhinitis in primary care:a cross-sectional study.Prim Care Respir J,2013,22(2):155-160.
[2]Paw ankar R.Allergic rhinitis and asthma:the link,the new ARIAclassific ation and globle approaches to treatment.Curr Opin Allergy Clin Immunol,2004,4(1):1-4.
[3]中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎的诊断和治疗指南(2009,武夷山)[J].中华耳鼻咽喉头颈外科杂志.2009,44(12):977-978.
[4]黄兆选,汪吉宝,孔维佳,主编.实用耳鼻咽喉头颈外科学.第二版.北京:人民卫生出版社,2008:218-225.
[5]Koils JK,Linden A.Interleukiu-l7 family members and inflammation.Immunity,2004;2l(4):467-476.
[6]Long A,McFadden C,DeVine D,et al.Management of allergic and nonallergic rhinitis.Evid Rep Technol Assess(Summ),2002,(54):1-6.
[7]王珍.RORγt及相关因子在大鼠实验性变应性鼻炎发病中的作用及滨蒿内酯干预研究.[学位论文],广东湛江:广东医学院,2014年:30-34.
[8]Pipet A,Botturi K,Pinot D,et al.Allergen-specific immunotherapy in allergicrhinitis and asthma.Mechanisms and proof of efficacy.Respir Med,2009,103:800-812.
[9]LaPan P,Zhang J,Pan J,et al.Quantitative optimization of reverse transfection conditions for 384-well siRNA library screening.Assay Drug Dev Technol,2008,6(5):683-691.
[10]Rauen T,Juang YT,Hedrich CM,et al.A novel isoform of the orphan receptor RORγt suppresses IL-17 production in human Tcells.Genes Immun,2012,13(4):346-350.
[11]Ivanov I.I,McKenzie BS,Zhou L,et al.The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+Thelper cells.Cell,2006,126(6):1121-1123.
[2]Paw ankar R.Allergic rhinitis and asthma:the link,the new ARIAclassific ation and globle approaches to treatment.Curr Opin Allergy Clin Immunol,2004,4(1):1-4.
[3]中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎的诊断和治疗指南(2009,武夷山)[J].中华耳鼻咽喉头颈外科杂志.2009,44(12):977-978.
[4]黄兆选,汪吉宝,孔维佳,主编.实用耳鼻咽喉头颈外科学.第二版.北京:人民卫生出版社,2008:218-225.
[5]Koils JK,Linden A.Interleukiu-l7 family members and inflammation.Immunity,2004;2l(4):467-476.
[6]Long A,McFadden C,DeVine D,et al.Management of allergic and nonallergic rhinitis.Evid Rep Technol Assess(Summ),2002,(54):1-6.
[7]王珍.RORγt及相关因子在大鼠实验性变应性鼻炎发病中的作用及滨蒿内酯干预研究.[学位论文],广东湛江:广东医学院,2014年:30-34.
[8]Pipet A,Botturi K,Pinot D,et al.Allergen-specific immunotherapy in allergicrhinitis and asthma.Mechanisms and proof of efficacy.Respir Med,2009,103:800-812.
[9]LaPan P,Zhang J,Pan J,et al.Quantitative optimization of reverse transfection conditions for 384-well siRNA library screening.Assay Drug Dev Technol,2008,6(5):683-691.
[10]Rauen T,Juang YT,Hedrich CM,et al.A novel isoform of the orphan receptor RORγt suppresses IL-17 production in human Tcells.Genes Immun,2012,13(4):346-350.
[11]Ivanov I.I,McKenzie BS,Zhou L,et al.The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+Thelper cells.Cell,2006,126(6):1121-1123.